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Background
Rare copy number variants (CNVs) are associated with risk of
neurodevelopmental disorders characterised by varying degrees
of cognitive impairment, including schizophrenia, autism spec-
trum disorder and intellectual disability. However, the effects of
many individual CNVs in carriers without neurodevelopmental
disorders are not yet fully understood, and little is known about
the effects of reciprocal copy number changes of known
pathogenic loci.
Aims
We aimed to analyse the effect of CNV carrier status on cognitive
performance and measures of occupational and social out-
comes in unaffected individuals from the UK Biobank.
Method
We called CNVs in the full UK Biobank sample and analysed data
from 420 247 individuals who passed CNV quality control,
reported White British or Irish ancestry and were not diagnosed
with neurodevelopmental disorders. We analysed 33 pathogenic
CNVs, including their reciprocal deletions/duplications, for
association with seven cognitive tests and four general mea-
sures of functioning: academic qualifications, occupation,
household income and Townsend Deprivation Index.
Results
Most CNVs (24 out of 33) were associated with reduced per-
formance on at least one cognitive test or measure of
functioning. The changes on the cognitive tests were modest
(average reduction of 0.13 s.d.) but varied markedly between
CNVs. All 12 schizophrenia-associated CNVs were associated
with significant impairments on measures of functioning.
Conclusions
CNVs implicated in neurodevelopmental disorders, including
schizophrenia, are associated with cognitive deficits, even
among unaffected individuals. These deficits may be subtle but
CNV carriers have significant disadvantages in educational
attainment and ability to earn income in adult life.
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Copy number variants (CNVs) are deletions or duplications of
>1000 DNA base pairs, resulting in altered dosage of the affected
sequence.1,2 Rare (frequency <1%) CNVs are associated with risk
of neurodevelopmental disorders, including intellectual disability,
autism spectrum disorder, attention-deficit hyperactivity disorder
and schizophrenia, disorders characterised by varying degrees of
cognitive impairment.3–8 Carriers of such CNVs can have cognitive
impairment even if they do not have such diagnoses. Previous work,
including our study of the first ∼150 000 individuals genotyped in
UK Biobank, has shown that unaffected individuals carrying neuro-
developmental CNVs, as a group, perform on cognitive tests inter-
mediately between CNV non-carriers and individuals with
schizophrenia, and have lower educational attainment and occupa-
tions requiring less training, compared with non-carriers.9–11 As a
group, rare deletion CNVs have also been associated with a decrease
in performance IQ in general population cohorts.12 Our previous
work lacked power to examine the effect of individual CNVs.
Since then, genotype data on a further ∼350 000 individuals have
been released. The aim of the present study was to examine the
effects of individual CNVs on cognitive function and on more
general measures of functioning, including educational perform-
ance and ability to earn income. Given pathogenic CNVs are
thought to exert their phenotypic effects via changes in gene
dosage, we also included in the analysis the reciprocal deletions/
duplications of known pathogenic CNVs, even if their role on cog-
nition has not been identified before.
Method
Participants
The UK Biobank recruited ∼500 000 individuals aged 40–69 years
(54% female) between 2006 and 2010. Participants underwent
phenotypic and cognitive testing at UK Biobank assessment
centres, and provided demographic, socioeconomic and health
data. Subgroups also completed follow-up testing in person and
online.Written informed consent was obtained from all participants
by the UK Biobank. All procedures involving human participants
were approved by the North West Multi-Centre Ethics Committee
(approval number 11/NW/0382). Data were released to Cardiff
University under application number 14421 ‘Identifying the spec-
trum of biomedical traits in adults with pathogenic copy number var-
iants (CNVs)’. The authors assert that all procedures contributing to
this work comply with the ethical standards of the relevant national
and institutional committees on human experimentation and with
the Helsinki Declaration of 1975, as revised in 2008.* These authors contributed equally to this work.
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To limit the analysis to unaffected individuals, we excluded 1021
individuals diagnosed with intellectual disability, autism spectrum
disorder or schizophrenia, (self-reported or diagnosed during hos-
pital admissions).
CNV calling and annotation
Samples were genotyped at Affymetrix Research Services
Laboratory (Santa Clara, California, USA) on two Affymetrix
arrays: ∼50 000 on the UK BiLEVE Array and ∼450 000 on the
UK Biobank Axiom Array. Quality control filters included geno-
typic call rate <0.96, waviness factor of <−0.03 and >0.03, >30
CNVs per person and log R ratio s.d. of >0.35. From 488 415
people with genotypic data, 25 061 were excluded for failing these
quality control filters. We further restricted analyses to individuals
of self-reportedWhite British or Irish ancestry, for a total of 420 247
individuals included in the analysis. Participants passing quality
control had an average of 6.57 CNVs called with ≥10 SNP probes.
Our CNV calling pipeline is described in detail elsewhere.10
Briefly, we downloaded raw intensity CEL files and processed them
with Affymetrix Power Tools (version 1.18.0 for Linux/OS X,
Affymetrix, US www.affymetrix.com/estore/partners_programs/
programs/developer/tools/powertools.affx) and PennCNV.13 We
compiled an initial list of 92 CNV regions that lead to genomic dis-
orders, or are implicated in intellectual disability, autism spectrum
disorder and congenital malformations, and their reciprocal dele-
tions or duplications, from two widely accepted sources.5,14 Most
of these CNVs have been shown to statistically increase risk for
developmental delay;5 however, the list includes the reciprocal
deletions/duplications of confirmed pathogenic CNVs, even if the
evidence for their pathogenicity in unclear. Details on the 92
CNV loci are available in our previous publications on the UK
Biobank.10,15 CNVs with fewer than five observations for any of
the seven cognitive tests, as well as three CNV loci that produced
frequent calls on arrays that failed quality control (false positives),
were excluded from analyses, resulting in 33 CNVs taken forward
for association analyses (Table 1). Five of the 12 known schizophre-
nia-associated CNVs7 had to be excluded from analyses, as fewer
than five carriers had completed one or more of the tests: deletions
at 15q13.3 (total n = 41), 22q11.2 (n = 8) and 3q29 (n = 7), and
duplications at the Williams–Beuren (n = 13) and the Prader–
Willi syndrome regions (n = 17). We only report their associations
with the general measures of functioning, where data is available on
most participants (Discussion).
Cognitive tests
Participants completed cognitive tests at UK Biobank recruitment
centres (http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100026) and
a subgroup completed follow-up testing online (http://biobank.ctsu.
ox.ac.uk/crystal/label.cgi?id=116). We analysed tests performed by at
least ∼20% of participants. Where the same test was performed at
baseline and follow-up, we chose the occasion when the test was com-
pleted by a higher number of people. In total, seven cognitive tests
were examined for association with individual CNVs. Before associ-
ation analyses, data were normalised, where required, and converted
to Z-scores as described previously.10
Pairs Matching Test
The Pairs Matching Test is a test of episodic memory and was com-
pleted by 419 861 individuals included in analyses. Participants were
shown 6 pairs of cards for 3 s and then asked to identify matching
pairs. We used the total number of errors for participants who com-
pleted the test as our outcome measure and applied a log + 1 trans-
formation to these data.
Reaction Time Test
The Reaction Time Test is a test of simple processing speed and was
completed by 417 461 individuals included in analyses. Participants
played 12 rounds of the game ‘Snap’, where they had to click a
button as quickly as possible when shown matching cards. We
used the mean reaction time to correct responses as our outcome
measure. A log transformation was applied to these data.
Fluid Intelligence Test
The Fluid Intelligence Test is a test of reasoning and problem
solving and was completed at baseline by 134 309 individuals
included in analyses. Participants completed as many verbal and
numerical reasoning questions as they could within 2 min. We
used the total number of correct answers as the outcome measure.
Digit Span Test
The Digit Span Test is a test of numeric working memory and was
completed at an online follow-up by 92 379 individuals included in
analyses. Participants were required to try to remember progres-
sively longer numbers and enter them once the number had disap-
peared from the screen. We used the maximum number of digits
remembered as our outcome measure.
Symbol Digit Substitution Test
The Symbol Digit Substitution Test is a test of complex processing
speed and was completed at the online follow-up by 102 042 indivi-
duals included in analyses. Participants were required to match as
many numbers to symbols as they could in a given time. We used
the number of correct substitutions as our outcomemeasure, exclud-
ing outliers (<3 and >36 substitutions). The remaining scores were
normally distributed and did not require transformation.
Trail Making Tests A and B
The Trail Making Tests A and B are tests of visual search speed,
scanning, speed of processing, mental flexibility and executive func-
tioning. They were completed by 90 106 individuals at online
follow-up. Participants were required to connect circles according
to numbers (test A) and alternating letters and numbers (test B).
We used the time taken to complete these tests as our outcome
measure. A log transformation was applied to these data.
General measures of functioning
Cognitive performance affects the educational attainment, func-
tioning and earning potential of people throughout their
lives.17–19 We chose to analyse four measures of functioning, with
data available on most participants: educational qualifications,
occupation, household income and Townsend Deprivation Index.20
Qualifications
We used the highest qualification an individual had achieved (e.g.
university/college degree, A-levels). After excluding participants
with only ‘other professional qualifications’ and those who did
not answer the question, we retained data for 394 575 participants,
as described previously.10
Occupation
We used the nine bands coding for occupations, based on the
required training or academic skills, as defined by the UK Office
of National Statistics.21 After excluding those who declined to
answer, or whose occupations could not be fitted into the nine
categories, we retained data for 257 788 participants.
Kendall et al
298
Household income
Annual income was categorised by the UK Biobank in five bands,
as follows: <£18,000, £18,000–30,999, £31,000–51,999, £52,000–
100,000 and >£100,000. Information was available on 361 812
included participants.
Townsend Deprivation Index
This is an index of social deprivation. Participants were assigned
deprivation scores based on their postal code at the time of recruit-
ment. The score is based on four variables: households without a car,
overcrowded households, households not owner occupied and
persons unemployed. Information was available on 419 756
included participants.
Statistical analyses
Analyses were performed in R (v3.3.2). For all cognitive tests and the
Townsend Deprivation Index we used linear regression analyses
(glm) with cognitive score as the dependent variable. We used
CNV carrier status as the independent variable and included as cov-
ariates age at the time of assessment, gender and array type (BiLEVE
or Axiom), and for the cognitive tests, measures of medical
comorbidity, psychotropic medication and alcohol intake, which
all negatively affected the cognitive tests. As a proxy for medical
comorbidity, we used the number of hospital admissions (log + 1
transformed); for psychotropic medication intake, we created four
separate variables for antipsychotics, antidepressants, benzodiaze-
pines and anti-epileptics, and for alcohol intake we used the self-
reported alcohol consumption frequency. Results are presented as
unstandardised regression coefficients (that equate to Z-score dif-
ferences between CNV carriers and non-carriers). Results for edu-
cational qualifications, occupation and household income, which
were analysed in ordinal regression analyses, are expressed as the
exponential of the odds of carriers being in a different band (e.g.
in a lower income bracket). For ease of interpretation, the directions
of all effects were adjusted in all tables and figures, so that a negative
sign always implies worse performance or outcome, e.g. longer time
to complete a test, fewer digits remembered, lower income and
higher Townsend Deprivation Index. To evaluate the significance
of results, we used the Benjamini–Hochberg false discovery rate
(FDR) method for P-value correction, as multiple true positive
results were expected. We accepted an FDR of 0.05 as our signifi-
cance threshold (i.e. we expect 5% of the results below that threshold
to be false positives).22
Results
The majority of tested CNVs (24 out of 33) were significantly asso-
ciated with at least one cognitive performance test or measure of
functioning (Table 1, Fig. 1). A total of 118 of the 363 individual
associations (32.5%) were significant at FDR <0.05. Full details
Table 1 CNVs examined in analyses
CNV locus
Genomic
location (Mb)
Number of
genes in CNV
Number of CNV
carriers (%)
Number of
significant results
Average
effect size Penetrance (%)
aTAR del chr1:145,39–145,81 17 75 (0.018) 0 −0.11 17
aTAR dup chr1:145,39–145,81 17 436 (0.1) 5 −0.12 7
b1q21.1 del chr1:146,53–147,39 9 112 (0.027) 7 −0.27 28
b1q21.1 dup chr1:146,53–147,39 9 176 (0.042) 5 −0.08 14
bNRXN1 del chr2:50,14–51,26 1 162 (0.039) 4 −0.19 13
a2q11.2 del chr2:96,74–97,68 22 31 (0.007) 1 −0.13 13
2q13 del (NPHP1) chr2:110,86–110,98 3 2446 (0.58) 0 −0.01 4
2q13 dup (NPHP1) chr2:110,86–110,98 3 1972 (0.47) 0 0.01 9
a2q13 del chr2:111,39–112,01 3 53 (0.013) 3 −0.16 17
a2q13 dup chr2:111,39–112,01 3 71 (0.017) 0 −0.02 6
2q21.1 dup chr2:131,48–131,93 5 59 (0.014) 0 0.07 9
a10q11.21q11.23 del chr10:49,39–51,06 19 57 (0.014) 4 −0.18 7
10q11.21q11.23 dup chr10:49,39–51,06 19 41 (0.01) 0 0.03 11
13q12 del (CRYL1) chr13:20,98–21,10 2 379 (0.09) 1 0.01 6
13q12.12 del chr13:23,56–24,88 10 84 (0.02) 2 −0.16 4
13q12.12 dup chr13:23,56–24,88 10 233 (0.055) 0 −0.01 3
b15q11.2 del chr15:22,81–23,09 5 1661 (0.39) 9 −0.15 8
a15q11.2 dup chr15:22,81–23,09 5 2039 (0.48) 5 −0.03 5
15q11q13 dup breakpoints 3 and 4 chr15:29,16–30,38 4 53 (0.013) 2 −0.18 4
15q13.3 dup chr15:31,08–32,46 8 240 (0.057) 6 −0.09 8
15q13.3 dup (CHRNA7) chr15:32,02–32,46 1 3023 (0.72) 1 0.01 5
a16p13.11 del chr16:15,51–16,29 7 131 (0.031) 6 −0.26 17
b16p13.11 dup chr16:15,51–16,29 7 825 (0.2) 7 −0.06 7
b16p12.1 del chr16:21,95–22,43 8 245 (0.058) 7 −0.10 11
16p12.1 dup chr16:21,95–22,43 8 198 (0.047) 0 −0.09 3
a16p11.2 distal del chr16:28,82–29,05 11 58 (0.014) 7 −0.41 23
a16p11.2 distal dup chr16:28,82–29,05 11 136 (0.032) 4 −0.20 11
a16p11.2 del chr16:29,65–30,20 30 104 (0.025) 7 −0.34 38
b16p11.2 dup chr16:29,65–30,20 30 134 (0.032) 8 −0.41 29
17p12 del (HNPP) chr17:14,14–15,43 8 237 (0.056) 0 0.01 5
17p12 dup (CMT1A) chr17:14,14–15,43 8 124 (0.030) 2 −0.04 9
a17q12 dup chr17:34,81–36,22 17 100 (0.024) 4 −0.18 14
a22q11.2 dup chr22:19,04–21,47 61 279 (0.066) 11 −0.32 14
The number of significant results is shown, using a threshold of false discovery rate of 0.05. The average effect size is the mean of the seven cognitive tests coefficients for that CNV from
regression analyses (a lower number indicates worse impairment). Penetrance data are based on Kirov et al,16 with control frequencies updated by UK Biobank data and indicate the
cumulative risk of CNV carriers to develop schizophrenia, autism spectrum disorder or intellectual disability. CNV, copy number variant; del, deletion; chr, chromosome; dup, duplication;
HNPP, hereditary neuropathy with liability to pressure palsies.
a. Neurodevelopmental CNV.
b. Schizophrenia-associated CNV.
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are given in Supplementary Table 1 and Figure 1 available at https://
doi.org/10.1192/bjp.2018.301.
Of the 118 significant results, 117 were in the direction of
reduced performance or function. The average effect size for the
seven cognitive tests was only −0.13 (range, −0.41 to 0.07), with
the worst performance among carriers of 16p11.2 deletions and
duplications, 16p11.2 distal deletions and 22q11.2 duplications
(range, −0.34 to −0.41). The single trend toward improved per-
formance (15q13.3 CHRNA7 duplication with qualifications) was
our least significant result, compatible with it being one of the
16p11.2 dup 17p12 dup CMT1A 17q12 dup 22q11.2 dup
16p13.11 dup 16p12.1 del 16p11.2 distal del 16p11.2 distal dup 16p11.2 del
15q11.2 dup 15q11q13 dup BP3_4 15q13.3 dup 15q13.3 dup CHRNA7 16p13.11 del
2q13 del 10q11.21q11.23 del 13q12 del CRYL1 13q12.12 del 15q11.2 del
TAR dup 1q21.1 del 1q21.1 dup NRXN1 del 2q11.2 del
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Fig. 1 Results of association analyses of pathogenic loci with seven cognitive tests and four measures of functioning for the 24 CNVs with at
least one significant result. The direction of effect is adjusted so that poorer performance/functioning is always indicated with a negative sign (to
the left of the zero-point vertical lines). The coefficients and 95% CIs are derived from linear regression analyses, except for income, occupations
and educational qualifications, which were analysed with ordinal regression analysis. Higher definition images for the effect sizes of all 33 CNVs
are presented in Supplementary Figure 1. CNV, copy number variant; del, deletion; dup, duplication.
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expected 5% false positives. This suggests that no CNV from this list
enhances cognitive function and there are no mirror phenotypes
caused by deletions and duplications at the same locus (i.e. deletion
impairing cognitive function and duplication enhancing it), some-
thing shown for some physical traits such as height and weight
among carriers of CNVs at the 16p11.2 locus.23,24 The 15q13.3
duplication had six significant associations. The reciprocal deletion
at this locus is a confirmed schizophrenia/intellectual disability/
autism spectrum disorder risk locus, but the duplication has not
yet been statistically confirmed as a neurodevelopmental CNV.5
Our results suggest that it is probably also a true intellectual
disability/autism spectrum disorder locus despite failing to reach
statistical support in the previous analysis.5 To test the robustness
of our findings, we performed permutation analysis of the six sig-
nificant results by randomly shuffling the carrier status of indivi-
duals 10 000 times and repeating the regression analysis. All six
results were robust to permutation testing (Supplementary Table 1).
Discussion
Associations between neurodevelopmental CNVs, as a group, and
impaired cognitive performance among individuals without neuro-
developmental disorders were expected given previous work by us
and others,9–11 and their associations with disorders characterised
by varying degrees of cognitive impairment.3,5–8 We have now
extended those findings to investigate the effects at the level of indi-
vidual CNVs among unaffected adults from the general population.
The effects tended to be modest, but the large sample size provided
sufficient statistical power to detect existing differences. The range
of impairments in carriers of deletions at NRXN1 and 15q11.2,
and duplications at 22q11.2 was larger than anticipated. In contrast,
no significant cognitive or functional impairment was observed in
carriers of nine CNVs: deletions/duplications at 2q13 (NPHP1),
TAR deletions, duplications at 2q13, 2q21.1, 10q11.21q11.23,
13q12.12 and 16p12.1, and deletions at 17p12 (a CNV that causes
the peripheral neurological disorder hereditary neuropathy with
liability to pressure palsies).
Cognitive impairment, penetrance of CNVs and
selection
The degree of cognitive impairment caused by each CNV can be
approximated by their mean effect sizes from all seven tests. We
hypothesised that there should be a positive correlation between
the degree of cognitive impairment and the penetrance of these
CNVs for thedevelopment of schizophrenia andotherneurodevelop-
mental disorders. We used penetrance estimates from previous
work,16 updated to include controls from the current UK Biobank
cohort (Table 1). There was a strong correlation between the pene-
trance of CNVs for neurodevelopmental disorders and the average
effect size of the seven cognitive tests among unaffected adult carriers
(Pearson’s correlation, 0.74; P = 10−6; Fig. 2a). Previous work
reported a strong association between IQ and the probability at
which CNV deletions occur de novo.23 This de novo probability
reflects the strength of natural selection pressure on CNV carriers
(de novo CNVs are filtered out by natural selection). There is a
high correlation between penetrance for neurodevelopmental disor-
ders and selection pressure, as we showed previously.16 Thus both
papers suggest that cognitive function is a leading factor influencing
the strength of selection pressure on CNV carriers. The selection
pressure can bemeasured by comparing the number of surviving off-
spring from individuals with and without CNVs. This is not possible
with the current data, as negative selection operates most strongly on
persons affectedwith intellectual disability, autism spectrumdisorder
and schizophrenia, who are excluded from this analysis. For
completeness, we provide data on the average number of offspring
in unaffected CNV carriers, compared with the controls’ average of
1.8, after controlling for gender and age (Supplementary Table 2).
Ten CNVs are associated with statistically significant reductions in
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Fig. 2 Correlation between the penetrance of CNVs for neurodevelopmental disorders (including intellectual disability, autism spectrum
disorder and schizophrenia) and (a) the average effect sizes on seven cognitive tests (Pearson correlation, 0.74) and (b) the average number of
children of CNV carriers (Pearson correlation, 0.78). * indicates neurodevelopmental CNV and ** indicates schizophrenia CNV. CNV, copy
number variant.
Cognitive and functional effects of pathogenic CNVs
301
the number of offspring, with the largest difference found for
carriers of 16p11.2 deletions, who have on average one child fewer
compared with controls. The reduction in the number of offspring
also correlates highly with the penetrance of CNVs for neurodevelop-
mental disorders (Pearson’s correlation, 0.78; P = 10−7; Fig. 2b).
These results indicate that unaffected carriers of certain CNVs
might also have deficits in socialising and forming families, likely
due to a combination of cognitive, medical and behavioural
problems.
CNVs and functioning
The available cognitive tests provide a cross-sectional measure of a
limited set of skills, and performance can be affected by random
factors, such as distraction during tests performed on home compu-
ters. In contrast, overall school results, occupational attainment, the
ability to earn an income and the degree of social deprivation in
middle age represent overall real-world functional outcomes averaged
across life. These measures of overall functioning showed an even
higher rate of significant deficits: 70 out of 132 comparisons (53%)
were significant at FDR = 0.05 (Fig. 1, Supplementary Table 1).
The cognitive effects of neurodevelopmental CNVs are an
obvious potential mediator for the relatively poor overall function-
ing of carriers. However, they might not be the only factor. To
explore this, we used the Fluid Intelligence Test score (the test
with the strongest correlation with measures of functioning) as a
covariate in regression analyses of measures of functioning. We
then compared results with and without Fluid Intelligence Test
score as a covariate (Supplementary Tables 3 and 4). The effect
size for associations of neurodevelopmental CNVs with household
income were modestly reduced, and they were almost unchanged
for the Townsend Deprivation Index. This finding is consistent
with the relatively low correlations between some of the cognitive
test results and measures of functioning (Supplementary Table 5).
This indicates that cognitive performance cannot account for the
entire effect of neurodevelopmental CNVs on functioning. Of
course, we cannot exclude the possibility that adjustment for
better measures of cognition, including social cognition, might
account for a greater proportion of the variance in these outcome
measures, but it is intuitively likely that non-cognitive factors are
also important. For example, associated medical problems can
also reduce the ability to earn an income. One factor that is unlikely
to play a role is the direct stigma of having a genetic disorder, as
these CNVs would not have been screened for during the early
life of the UK Biobank participants, when genetic testing is normally
performed. It is, however, possible that some carriers display subtle
physical features that might have resulted in discrimination; for
example, mild dysmorphic features. Regardless of the cause, CNV
carrier status should not be viewed as a deterministic factor in func-
tional outcomes, as poor physical health and social disadvantage can
be addressed and treated.
Schizophrenia-associated CNVs
CNVs robustly associated with risk for schizophrenia were consist-
ently associated with impaired cognitive performance and measures
of functioning: the seven CNVs analysed (out of 12 confirmed
loci)7,8 were significantly associated with between four and nine
tests/measures (Table 1). The remaining five CNVs (deletions at
15q13.3, 22q11.2 and 3q29, and duplications at the Williams-
Beuren and Prader-Willi syndrome regions) are among the most
highly penetrant for neurodevelopmental disorders,16 but were
too rare to analyse. For completeness, we present the data for all
12 schizophrenia-associated CNVs for association with measures
of functioning, which were available for most individuals. All 12
CNVs were associated with reduced functioning, with 45 out of
Qualifications Jobs Income
Townsend
Deprivation Index
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Coefficient
Fig. 3 Analysis of associations between 12 schizophrenia-associated CNVs and measures of functioning. The ‘coefficients’ indicate the effect
sizes and 95% CIs of the effect sizes from the regression analysis (Methods). All effects are in the direction of worse functioning (to the left of the
zero-point vertical lines). CNV, copy number variant; del, deletion; dup, duplication.
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the 48 comparisons reaching nominal levels of statistical signifi-
cance (Fig. 3, Supplementary Table 6).
The UK Biobank consists of individuals who are healthier and
have higher levels of education than the general population
because of self-selection bias.25 It is also relatively depleted of indi-
viduals with neurodevelopmental disorders: e.g. only 52 individuals
passing quality control had a known diagnosis of autism spectrum
disorder and 802 had a diagnosis of schizophrenia, instead of the
expected ∼1% each (∼4000 persons) under no selection bias. We
excluded such individuals from the analyses. Consequently, our
analyses underestimate the effect sizes of the more pathogenic
CNVs which are rare in this population, as the most affected carriers
are not ascertained. We show that in this population, certain neuro-
developmental CNVs are also associated with significant impair-
ments in cognition. The effects on the level of household income
among carriers of schizophrenia-associated CNVs are particularly
striking, given that these carriers do not have such diagnoses
(Fig. 3). These effects are not fully mediated by the measures of cog-
nitive function available in the UK Biobank and cannot be explained
by any stigma associated with a genetic disorder.
Limitations
One limitation in the data is in the type of cognitive tests used: to
maximise adherence, the chosen cognitive tests had to be adminis-
tered quickly. They cannot test all types of cognitive abilities in great
detail. In addition, very few individuals had completed all seven cog-
nitive tests, making it impractical to calculate a general intelligence
factor (g), as power would be severely affected. Instead, we decided
to report all seven tests separately, thus increasing multiple testing.
The ‘average effect size’ that we use (Table 1, Fig. 2a) is an imperfect
measure because it assumes equal weight for each test, and because
carriers of different CNVs did not complete identical sets of tests.
These problems also prevented us from establishing potential spe-
cific cognitive signatures of individual CNVs.
In conclusion, CNVs are increasingly being identified in
patients with neurodevelopmental disorders, including schizophre-
nia. The outcome of carrying a CNV can be mild and consistent
with high levels of social and economic functioning. However,
this varies according to the specific CNV involved, and certain
rare neurodevelopmental CNVs are particularly associated with
functional deficits that can amount to a full band lower on the
various scales (e.g. one lower household income bracket), even
among apparently healthy carriers. Patients and their families will
want to learn more about their genetic condition and will be con-
cerned about the impact on relatives who may have inherited the
CNV. Psychiatrists will therefore be required to be fully informed
about the range of outcomes possible in unaffected relatives.
Clinicians who request CNV testing should first ensure that patients
and their families receive appropriate pre- and post-test counselling.
Finally, the fact that the CNVs studied can be associated with out-
comes of such variable severity indicates the presence of modifying
factors (genetic and environmental) that may be tractable to inter-
vention. This is of profound interest and importance, and warrants
future research.
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Psychiatry
in Pictures
Reflections on The Elementary Forms of Religious Life
George Ikkos and Daniel McQueen
The Elementary Forms of Religious Life was first published in 1912. It is a text that relies on accounts by others of pre-20th cen-
tury lives of Australian Aborigines. It was written by Emile Durkheim (1858–1917), the son of a 3rd generation rabbi, who himself
was a committed Atheist. Durkheim was a philosopher by training and, initially a Lycée teacher, he remained a pedagogue
throughout life. He was the first appointed French professor of sociology, initially in Bordeaux and then in Paris. He is better
known to psychiatrists for his book Suicide (1897); he formed a formidable research team and published a succession of seminal
works including The Division of Labour in Society (1893) and The Rules of Sociological Method (1895), and established the foun-
dational and still-live professional journal L’Année Sociologique. His associates peopled the chairs of social science depart-
ments across France and beyond.
Elementary Forms is armchair sociology at its best. Having considered religion to be the foundation of anything that might be
legitimately called society, Durkheim relished the opportunity to make sense of what was the best available living evidence of
the earliest origins of religion. Dismissing psychologistic and animistic explanations in this book, he sought understanding in
social facts. There are careful descriptions of the terms clan, tribe, totem and religion (transcendental or not). He also describes
the nature of the sacred and profane, the soul and magic. Durkheim made the then radical claim that the minds of Aborigines
were no less sophisticated than those of contemporary Europeans. In this book Durkheim claimed that Totemism, which relies
on the perception of and belief in specific affinities and distinctions between different individuals, clans, tribes, objects and nat-
ural phenomena, was the first step towards modern science.
Totemism and science share the categorising of observed phenomena, making causal inferences and depending on peer con-
sensus. He saw the experience of the sacred and the rise of Totemism as a response to the bewildering intensity of feeling
experienced by family groups, normally living isolated and dull lives, when they came together with others in larger groups.
He referred to observers’ reports of their appearing overpowered and running wild, gesticulating, copulating or aggressing
as each small group joined others. In the face of such ‘effervescence’ they developed beliefs in a superior force (he adopts
the Melanesian word ‘mana’ for this).Mana penetrates people and connects them to others and their environment. He argued
that, though serving as foundation of religious belief, it is not perceived as transcendental, ergo religion is a natural social
phenomenon.
The book’s most profound implication is that organised social existence and Totemism imply each other and, through the
experience of effervescence and the practice of ritual, Totemism encompasses the activities through which social meaning
is expressed. Though education and convention havemoderated our responses over time – street gangs; the attraction of presi-
dential inaugurations and royal weddings; moral panics; epidemic hysterias; and clusters of cult suicides – even our own experi-
ences at conferences and at work confirm the enduring importance of mana (and effervescence) in our daily life.
Reflecting a dedicated study of evidence and illuminated by brilliant conceptual analysis, Elementary Forms remains a work of
formidable originality and immediate relevance, and is the best introduction to understanding in abstract and concrete detail the
living force of the ‘social’ in the biopsychosocial model of psychiatry.
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